**Algorae Pharmaceuticals – Shares out of Escrow**

**ASX: 1AI** | 18 November 2026

Algorae Pharmaceuticals Limited (ASX: 1AI) ("Algorae" or "the Company") advises that, in accordance with ASX Listing Rule 3.10A, 500,000 fully paid ordinary shares are due to be released from voluntary escrow on 25 November 2026.

**Authorised for release by the Board of Directors of Algorae Pharmaceuticals Ltd**

**END.**

**Corporate and Media Enquiries**

Mr David Hainsworth

Executive Chairman

E: investors@algoraepharma.com

**About Algorae Pharmaceuticals**

Algorae Pharmaceuticals (ASX: 1AI) is an AI-enabled pharmaceutical company with a dual focus on drug-combination discovery and pharmaceutical commercialisation. The Company's proprietary AI platform, AlgoraeOS, applies machine learning and deep neural networks to identify synergistic drug combinations and guide dose selection for preclinical development. In parallel, Algorae operates a commercialisation business, AlgoraeRx, that sources, licenses and supplies generic and specialty medicines in Australia and New Zealand through partnered manufacturers and established distribution channels. Algorae collaborates with leading research institutions and industry partners to translate AI-predicted therapies and to expand patient access to high-quality medicines.

Algorae is listed and publicly traded on the Australian Securities Exchange (ASX: 1AI), providing investors an opportunity to participate in the Company's growth.

For more information visit www.algoraepharma.com or follow @algoraepharma on X or LinkedIn.